Journal Articles

Management of prostate cancer in 2022

Lead Editor:

    Dr Carole Hélissey
    Military Hospital Begin
    France

From emerging new hormonotherapy, PARP inhibitors, to metabolic therapy. The development of these treatments initially in monotherapy and later in combination therapy has clearly improved the survival of patients at first in the metastatic stage and today in the localized stage. However, which treatment for each patient? When to introduce it? How to monitor the effectiveness, beyond the PSA, which imaging? Theranostic should now be developed for patients with prostate cancer. More than 85% of patients will be alive 5 years after their diagnosis, all stages combined, so the quality of life of these patients is important. In this Special Issue, we invite research that highlights further advances in prostate cancer diagnostic, therapies, patient care.


Submission deadline: 29/12/2022


Journal Cover

Print ISSN: 1792-1074
Online ISSN: 1792-1082

Sign up for eToc alerts

Recommend to Library

Full Size Image